Mesoblast Limited files as an Australian foreign private issuer, and its SEC reports document ASX announcements for its ADR-listed securities. Form 6-K reports incorporate Appendix 4C activity reports, press releases and R&D materials covering Ryoncil commercialization, operating cash spend, clinical programs for rexlemestrocel-L and Ryoncil, FDA regulatory updates and the company’s mesenchymal lineage cell therapy platform.
The filing record also documents capital-structure and governance matters through ASX appendices for proposed and quoted securities, unquoted equity securities, cessation of securities and changes in director interests. These disclosures connect Mesoblast’s public reporting to product revenue, pipeline development, equity issuance and foreign-issuer compliance under Form 20-F reporting.
Mesoblast Ltd director William Murray Burns filed an initial Form 3 showing his beneficial holdings in the company. The filing lists several option awards over Ordinary Shares with exercise prices ranging from $0.36 to $1.81 per share and expirations between 2026 and 2031. It also reports direct ownership of 226,250 Ordinary Shares as of the reporting date. These entries reflect existing positions rather than new purchases or sales.
Mesoblast Ltd CEO and Managing Director Silviu Itescu reported his existing ownership of Ordinary Shares and stock options. He directly holds 67,756,838 Ordinary Shares and has additional indirect holdings through entities associated with him. He also holds multiple option awards over Ordinary Shares with exercise prices from 0.3500 to 2.4600 per share, expiring between 2026 and 2032.
Mesoblast Ltd CEO and Managing Director Silviu Itescu has filed an initial Form 3 detailing his beneficial ownership in the company. The filing lists substantial direct holdings of Mesoblast ordinary shares along with additional shares held indirectly through entities associated with him.
It also discloses multiple option awards over Mesoblast ordinary shares at exercise prices ranging from $0.01 to $3.39 per share, with expirations extending out to 2031. These options provide the right to acquire additional ordinary shares if exercised before their respective expiration dates.
Mesoblast Ltd director George Gregory filed an initial ownership report listing his existing holdings in the company. The filing shows direct and indirect positions in ordinary shares, American Depositary Shares, warrants, and stock options with various exercise prices and expirations. A footnote explains that each ADS represents a beneficial interest in 10 ordinary shares.
Mesoblast Limited furnished a Form 6-K summarizing Australian Securities Exchange disclosures about director equity awards and other unquoted securities. The filing attaches Appendix 3Y notices showing option grants, with no cash consideration, to multiple directors following shareholder approval at the 2025 annual general meeting.
Chief Executive Officer Dr Silviu Itescu received 2,025,600 new options, increasing his option holdings to 18,475,158 while his 78,958,928 ordinary shares were unchanged. Director Dr Eric Rose received 820,000 options, bringing his total to 6,413,451 options with 6,749,274 ordinary shares unchanged. Director Gregory George received 200,000 options to acquire ordinary shares under the employee share option plan. Director Lyn Cobley received 200,000 options, adding to her existing direct and indirect shareholdings. The 6-K also forwards an Appendix 3G notice on unquoted equity securities.
Mesoblast Ltd director Philip R. Krause has filed an initial ownership report showing his equity position in the company. He directly holds 287,500 Ordinary Shares, which are represented by American Depositary Shares. In addition, he holds multiple option awards over Ordinary Shares with exercise prices between $0.32 and $0.99 per share and expirations ranging from 2029 to 2031. Footnotes indicate that certain options were granted in 2023 and 2024 and are scheduled to vest between October 24, 2026 and August 27, 2027, aligning his compensation with the company’s long-term performance.
Mesoblast Limited has filed a Form 6-K highlighting plans for its inaugural R&D Day on April 8, 2026, in New York City. The event will run from 8:00am to 11:00am EST and be webcast live for global access.
Senior leadership and external experts will present on corporate strategy, commercialization of flagship product Ryoncil®, and multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. Mesoblast will also unveil new technology intended to support the next era of cellular medicines.
The disclosure reiterates that Mesoblast develops allogeneic cellular therapies for severe inflammatory conditions, including FDA-approved Ryoncil® for pediatric steroid-refractory acute graft versus host disease, and is advancing remestemcel-L and rexlemestrocel-L programs with global partnerships, extensive patents, and proprietary large-scale manufacturing.
Mesoblast Ltd director George Gregory filed an initial Form 3 detailing his derivative holdings in MESO. The filing lists indirect warrants over 6,830,602 ordinary shares at an exercise price of $2.86 expiring in 2028, plus direct warrants over 200,000 ADS at $9.06 and 1,600,000 ordinary shares or ADS at $2.50 expiring between 2028 and 2029.
He also holds three option tranches over 66,667, 66,667 and 66,666 ordinary shares at $1.72 per share, which become exercisable between 2026 and 2028 and expire in 2032. The Form 3 reports these existing positions and does not show new purchases or sales.
Mesoblast Limited reported that Dr. Teresa Montagut, MD, PhD, has been appointed to the newly created role of Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose. She will lead medical affairs, clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals.
Dr. Montagut previously held senior medical and development roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics, and trained at leading U.S. institutions including Memorial Sloan Kettering Cancer Center. The company highlights her importance in advancing Ryoncil®, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and in expanding Mesoblast’s broader inflammatory disease and cell therapy pipeline.
Mesoblast Limited reported a sharp jump in activity for the half-year ended December 31, 2025, as the U.S. launch of Ryoncil drove total revenue to US$51.3 million, up from US$3.2 million a year earlier. Net loss narrowed to US$40.2 million from US$47.9 million, helped by high Ryoncil gross margins and tight cost control.
Ryoncil generated US$48.7 million of revenue and a gross profit of US$44.2 million, funding increased R&D spending of US$46.2 million on late-stage programs in chronic low back pain and heart failure. The company ended the period with cash of US$129.975 million, access to a US$125.0 million five-year credit line, and guided full-year fiscal 2026 Ryoncil net revenue to US$110–120 million.